22.51 USD
↗ 1.44 (6.83%)AT CLOSE (11:59 AM EDT)
Viridian Therapeutics, Inc. Common Stock
VRDNNASDAQ • USD
22.28
↘ 0.24 (1.04%)
POST MARKET (AS OF 07:52 PM EDT)
Post Market
AS OF 07:52 PM EDT
22.28
↘ 0.24 (1.04%)
Market: CLOSED
Viridian Therapeutics, Inc. Common Stock (VRDN) trades at $22.51 per share. Technicals currently rate "Buy" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation front, VRDN trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Aug 6, 2026.
Open?$20.94
High?$22.52
Low?$20.53
Prev. Close?$21.07
Volume?4.3M
Avg. Volume?2.2M
VWAP?$22.07
Rel. Volume?1.95x
Bid / Ask
Bid?$18.36 × 100
Ask?$26.40 × 100
Spread?$8.04
Midpoint?$22.38
Valuation & Ratios
Market Cap?2.3B
Shares Out?103.1M
Float?95.5M
Float %?86.5%
P/E Ratio?N/A
P/B Ratio?3.66
EPS?-$2.75
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Employees
252
Market Cap
2.3B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2014-06-18
Address
221 CRESCENT STREET
WALTHAM, MA 02453
Phone: 617.272.4600
WALTHAM, MA 02453
Phone: 617.272.4600
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?100
Momentum?62
Short Sent.?40
Piotroski F-Score?1/9Weak
Altman Z-Score?6.15Safe
Confidence?55%Low
Short InterestHigh
Short % of Float?19.81%High
Short Interest?18.9M
Days to Cover?9.9
Free Float95.5M
Avg Daily Volume1.9M
Settlement Date2026-07-15
Financial Health
Current Ratio?15.15Strong
Quick Ratio?15.15Strong
Cash Ratio?3.40Strong
Debt/Equity?0.14Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?3.66FAIR▾
Peers100
S&P47
P/S?32.81HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-5.8CHEAP▾
S&P97
EV/Sales?31.54HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-47.7%WEAK▾
S&P3
ROA?-38.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-303824000
Enterprise Value?$2.2B
Fundamentals ratios updated end of day